$RDNT

RadNet, Inc.

RadNet provides diagnostic imaging services to patients, physicians, hospitals and health systems in the United States. As of December 31, 2025, it operated 418 imaging centers, directly or through hospital and health system joint ventures, in Arizona, California, Delaware, Florida, Maryland, Virginia, New Jersey, Texas and New York. Its Imaging Centers segment offers MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray, fluoroscopy and related procedures. RadNet earns fees for imaging equipment use and technical services, as well as management fees and a portion of medical practice billings or collections under agreements with radiology groups. Payments come from commercial insurers, managed care arrangements, government programs and other providers. Its Digital Health segment sells computerized imaging systems and develops AI-enabled health informatics software. Products include eRad RIS/PACS and DeepHealth OS, a cloud-native platform for radiology operations. RadNet also provides teleradiology services through its majority-owned UK subsidiary, serving providers within the National Health Service framework. Its corporate headquarters is in Los Angeles, California.

No enriched coverage for $RDNT in the last 7 days.

—
$3.5M
Patel Mital
0%
See all $RDNT insider activity →
Low

Patel Mital sold $3.5M of RDNT

Patel Mital (EVP, Chief Operating Officer) sold 44,661 shares of RadNet, Inc. (RDNT) at $78.51 ($3.51M total) on 2026-11-11.

KeyBanc raises RadNet stock price target to $95 on imaging growth

KeyBanc raised its price target on RadNet (RDNT) to $95 from $92, citing strong Q3 results with a 7% EBITDA beat driven by advanced imaging growth. The stock has surged 35% in six months, trading at $78.38. KeyBanc and Truist Securities maintain Overweight and Buy ratings, respectively, highlighting long-term growth potential from AI and digital health initiatives.

RadNet Q3 Earnings Call Highlights

RadNet reported Q3 Digital Health revenue up 33% to $32.9M, with adjusted EBITDA at $3M. The segment closed $71M in contracts, including a $53M long-term deal. Annual recurring revenue grew 67% to $112.6M. RadNet raised 2026 imaging revenue guidance to $2.385B-$2.435B and adjusted EBITDA to $350M-$363M. It plans to acquire ONRAD for $350M in cash and 5M shares, expecting $190M-$200M in first-year revenue.

RDNT sentiment & insider activity

Recent RDNT coverage spans earnings, mergers & acquisitions and insider activity.

In the last 30 days, RDNT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($3.5M). The most active reporter was Patel Mital, EVP, Chief Operating Officer, with 1 filing.

What's driving RDNT

AlphAI scores every news story that mentions RDNT with an AI model for sentiment and relevance, and aggregates insider trades from RadNet, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RDNT

Score

KeyBanc raises RadNet stock price target to $95 on imaging growth

KeyBanc raised its price target on RadNet (RDNT) to $95 from $92, citing strong Q3 results with a 7% EBITDA beat driven by advanced imaging growth. The stock has surged 35% in six months, trading at $78.38. KeyBanc and Truist Securities maintain Overweight and Buy ratings, respectively, highlighting long-term growth potential from AI and digital health initiatives.

RadNet Q3 Earnings Call Highlights

RadNet reported Q3 Digital Health revenue up 33% to $32.9M, with adjusted EBITDA at $3M. The segment closed $71M in contracts, including a $53M long-term deal. Annual recurring revenue grew 67% to $112.6M. RadNet raised 2026 imaging revenue guidance to $2.385B-$2.435B and adjusted EBITDA to $350M-$363M. It plans to acquire ONRAD for $350M in cash and 5M shares, expecting $190M-$200M in first-year revenue.

$RDNTHighAI 8/10Earnings

RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

RadNet, Inc. (RDNT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2026 Financial Guidance Ranges · Total Company Revenue increased 22.1% to $638.3 million in the third quarter of 2026 from $

Rx Rundown: Ferring Pharmaceuticals, Gilead Sciences, Artiva Biotherapeutics and more

Ferring Pharmaceuticals agreed to acquire Gameto for $1.4B. Gilead Sciences will buy PepStar Therapeutics' oral IL-23R inhibitor program for $1.275B. Zymeworks partnered with Roche for T-cell engager ZW209. Astellas secured an option to license Audax Biosciences' immuno-oncology asset. Teva finalized a Medicaid cost-lowering agreement. Pfizer's Talzenna gained FDA approval for prostate cancer. Artiva Biotherapeutics laid off 94% of its workforce. Star Therapeutics raised $200M in funding.

RadNet acquires ONRAD in $355m deal to broaden radiology provision

RadNet agreed to acquire ONRAD for $355m ($350m cash, $5m shares) with a potential $210m earnout. The deal, expected to close in early 2027, aims to expand RadNet's radiology services and address staffing shortages. RadNet plans to integrate ONRAD's teleradiology and staffing services with its AI-based solutions to improve efficiency and patient care. Jefferies analysts called it a 'sound transaction.'

$RDNTHighM&A· acquirer · $350M · definitive

RadNet, Inc. (RDNT): Entry into a Material Definitive Agreement

RadNet, Inc. (RDNT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet, Inc. Announces Agreement to Acquire ONRAD, Inc. · Adds a radiology professional services platform offering teleradiology and in-hospital staffing for hospitals and health systems · Enables RadNet to seamlessly combine radiology professio

Q2 Earnings Outperformers: Labcorp (NYSE:LH) And The Rest Of The Testing & Diagnostics Services Stocks

Labcorp and other testing & diagnostics services stocks reported Q2 earnings. RadNet (RDNT) reported $622.7M revenue, up 25% YoY, but stock is down 8%. NeoGenomics (NEO) reported $201.7M revenue, up 11.2%, and stock is up 26.4%. Quest (DGX) reported $3.04B revenue, up 10.2%, and stock is up 11.3%. Guardant Health (GH) reported $335M revenue, up 44.3%, and stock is up 6%.

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

Related tickers